LaunchCyte creates company to push Penn University technology:
This article was originally published in Clinica
A venture capital company partly funded from the proceeds of the US state of Pennsylvania's successful settlement with the tobacco industry, is to set up a company to commercialise proteomics and enzyme assay. LaunchCyte will spin off Morewood Molecular to utilise new technology from the University of Pennsylvania. LaunchCyte claims to work in the field of "digital biology", seeking out marketing solutions at the point where life sciences and computing converge.